These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 37086780)

  • 21. Establishing a cost-per-result of laboratory-based, reflex Cryptococcal antigenaemia screening (CrAg) in HIV+ patients with CD4 counts less than 100 cells/μl using a Lateral Flow Assay (LFA) at a typical busy CD4 laboratory in South Africa.
    Cassim N; Schnippel K; Coetzee LM; Glencross DK
    PLoS One; 2017; 12(2):e0171675. PubMed ID: 28166254
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Association of Antibody Immunity With Cryptococcal Antigenemia and Mortality in a South African Cohort With Advanced Human Immunodeficiency Virus Disease.
    Yoon H; Wake RM; Nakouzi AS; Wang T; Agalliu I; Tiemessen CT; Govender NP; Jarvis JN; Harrison TS; Pirofski LA
    Clin Infect Dis; 2023 Feb; 76(4):649-657. PubMed ID: 35915964
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Serum cryptococcal antigen titre as a diagnostic tool and a predictor of mortality in HIV-infected patients with cryptococcal meningitis.
    Chen J; Zhang R; Shen Y; Liu L; Qi T; Wang Z; Mehraj V; Routy JP; Lu H
    HIV Med; 2019 Jan; 20(1):69-73. PubMed ID: 30311440
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Implementation and Operational Research: Evaluation of a Public-Sector, Provider-Initiated Cryptococcal Antigen Screening and Treatment Program, Western Cape, South Africa.
    Vallabhaneni S; Longley N; Smith M; Smith R; Osler M; Kelly N; Cross A; Boulle A; Meintjes G; Govender NP
    J Acquir Immune Defic Syndr; 2016 Jun; 72(2):e37-e42. PubMed ID: 26926942
    [TBL] [Abstract][Full Text] [Related]  

  • 25. LATERAL FLOW ASSAY FOR CRYPTOCOCCAL ANTIGEN: AN IMPORTANT ADVANCE TO IMPROVE THE CONTINUUM OF HIV CARE AND REDUCE CRYPTOCOCCAL MENINGITIS-RELATED MORTALITY.
    Vidal JE; Boulware DR
    Rev Inst Med Trop Sao Paulo; 2015 Sep; 57 Suppl 19(Suppl 19):38-45. PubMed ID: 26465368
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prospective cohort of AIDS patients screened for cryptococcal antigenaemia, pre-emptively treated and followed in Brazil.
    Borges MASB; de Araújo Filho JA; Oliveira BJS; Moreira IS; de Paula VV; de Bastos AL; Soares RBA; Turchi MD
    PLoS One; 2019; 14(7):e0219928. PubMed ID: 31344140
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Cost-Effectiveness Analysis of the Implementation of Cryptococcal Antigen Lateral Flow Assay for the Diagnosis of Cryptococcal Meningitis in Symptomatic People Living With Human Immunodeficiency Virus in Brazil.
    Vianna CMM; Mosegui GBG
    Value Health Reg Issues; 2022 May; 29():53-59. PubMed ID: 34801886
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Reflexive Laboratory-Based Cryptococcal Antigen Screening and Preemptive Fluconazole Therapy for Cryptococcal Antigenemia in HIV-Infected Individuals With CD4 <100 Cells/µL: A Stepped-Wedge, Cluster-Randomized Trial.
    Meya DB; Kiragga AN; Nalintya E; Morawski BM; Rajasingham R; Park BJ; Mubiru A; Kaplan JE; Manabe YC; Boulware DR
    J Acquir Immune Defic Syndr; 2019 Feb; 80(2):182-189. PubMed ID: 30399034
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Universal screening of Tanzanian HIV-infected adult inpatients with the serum cryptococcal antigen to improve diagnosis and reduce mortality: an operational study.
    Wajanga BM; Kalluvya S; Downs JA; Johnson WD; Fitzgerald DW; Peck RN
    J Int AIDS Soc; 2011 Oct; 14():48. PubMed ID: 21988905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. CD4 Cell Count Threshold for Cryptococcal Antigen Screening of HIV-Infected Individuals: A Systematic Review and Meta-analysis.
    Ford N; Shubber Z; Jarvis JN; Chiller T; Greene G; Migone C; Vitoria M; Doherty M; Meintjes G
    Clin Infect Dis; 2018 Mar; 66(suppl_2):S152-S159. PubMed ID: 29514236
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Benefits of enhanced infection prophylaxis at antiretroviral therapy initiation by cryptococcal antigen status.
    Pett SL; Spyer M; Haddow LJ; Nhema R; Benjamin LA; Najjuka G; Bilima S; Daud I; Musoro G; Kitabalwa J; Selemani G; Kandie S; Cornelius KM; Katemba C; Berkley JA; Hassan AS; Kityo C; Hakim J; Heyderman RS; Gibb DM; Walker AS;
    AIDS; 2021 Mar; 35(4):585-594. PubMed ID: 33306556
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Cost-effectiveness analysis and budgetary impact of the Cryptococcal Antigen Lateral Flow Assay (CRAG-LFA) implementation for the screening and diagnosis of cryptococcosis in asymptomatic people living with HIV in Brazil.
    Vianna CMM; Mosegui GBG
    Rev Inst Med Trop Sao Paulo; 2021; 63():e57. PubMed ID: 34231822
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Screening for cryptococcal antigen in asymptomatic people with HIV: urgent need in Eastern India.
    Chakravarty J; Reddy S; Gupta MK; Tilak R; Diwaker C; Sundar S
    AIDS; 2023 Dec; 37(15):2359-2363. PubMed ID: 37650766
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cost-effectiveness of CRAG-LFA screening for cryptococcal meningitis among people living with HIV in Uganda.
    Ramachandran A; Manabe Y; Rajasingham R; Shah M
    BMC Infect Dis; 2017 Mar; 17(1):225. PubMed ID: 28335769
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Prevalence of cryptococcal antigenemia and cost-effectiveness of a cryptococcal antigen screening program--Vietnam.
    Smith RM; Nguyen TA; Ha HT; Thang PH; Thuy C; Lien TX; Bui HT; Le TH; Struminger B; McConnell MS; Fanfair RN; Park BJ; Harris JR
    PLoS One; 2013; 8(4):e62213. PubMed ID: 23626792
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Inadequacy of High-Dose Fluconazole Monotherapy Among Cerebrospinal Fluid Cryptococcal Antigen (CrAg)-Positive Human Immunodeficiency Virus-Infected Persons in an Ethiopian CrAg Screening Program.
    Beyene T; Zewde AG; Balcha A; Hirpo B; Yitbarik T; Gebissa T; Rajasingham R; Boulware DR
    Clin Infect Dis; 2017 Nov; 65(12):2126-2129. PubMed ID: 29020172
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of serum cryptococcal antigen screening to prevent deaths among HIV-infected persons with a CD4+ cell count < or = 100 cells/microL who start HIV therapy in resource-limited settings.
    Meya DB; Manabe YC; Castelnuovo B; Cook BA; Elbireer AM; Kambugu A; Kamya MR; Bohjanen PR; Boulware DR
    Clin Infect Dis; 2010 Aug; 51(4):448-55. PubMed ID: 20597693
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The global burden of HIV-associated cryptococcal infection in adults in 2020: a modelling analysis.
    Rajasingham R; Govender NP; Jordan A; Loyse A; Shroufi A; Denning DW; Meya DB; Chiller TM; Boulware DR
    Lancet Infect Dis; 2022 Dec; 22(12):1748-1755. PubMed ID: 36049486
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Brief Report: Point of Care Cryptococcal Antigen Screening: Pipetting Finger-Prick Blood Improves Performance of Immunomycologics Lateral Flow Assay.
    Wake RM; Jarvis JN; Harrison TS; Govender NP
    J Acquir Immune Defic Syndr; 2018 Aug; 78(5):574-578. PubMed ID: 29771787
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Outcomes of flucytosine-containing combination treatment for cryptococcal meningitis in a South African national access programme: a cross-sectional observational study.
    Mashau RC; Meiring ST; Quan VC; Nel J; Greene GS; Garcia A; Menezes C; Reddy DL; Venter M; Stacey S; Madua M; Boretti L; Harrison TS; Meintjes G; Shroufi A; Trivino-Duran L; Black J; Govender NP;
    Lancet Infect Dis; 2022 Sep; 22(9):1365-1373. PubMed ID: 35750065
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.